Samuel Oliveira

Samuel Oliveira

Auto-generated profile, based on publicly available information

Samuel Oliveira

Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TRTamara S. Rodrigues
Tamara S. Rodrigues
KSKeyla Sá
Keyla Sá
AIAdriene Y. Ishimoto
Adriene Y. Ishimoto
ABAmanda Becerra
Amanda Becerra
SOSamuel Oliveira
Samuel Oliveira
DZDario S. Zamboni
Dario S. Zamboni
Severe cases of COVID-19 are characterized by a strong inflammatory process that may ultimately lead to organ failure and patient death. The NLRP3 inflammasome is a molecular platform that promotes inflammation via cleavage and activation of key inflammatory molecules including active caspase-1 (Casp1p20), IL-1β, and IL-18. Although participation of the inflammasome in COVID-19 has been highly speculated, the inflammasome activation and participation in the outcome of the disease are unknown. Here we demonstrate that the NLRP3 inflammasome is activated in response to SARS-CoV-2 infection and is active in COVID-19 patients. Studying moderate and severe COVID-19 patients, we found active NLRP3 inflammasome in PBMCs and tissues of postmortem patients upon autopsy. Inflammasome-derived products such as Casp1p20 and IL-18 in the sera correlated with the markers of COVID-19 severity, including IL-6 and LDH. Moreover, higher levels of IL-18 and Casp1p20 are associated with disease severity and poor clinical outcome. Our results suggest that inflammasomes participate in the pathophysiology of the disease, indicating that these platforms might be a marker of disease severity and a potential therapeutic target for COVID-19.

16 September 2022 in Science Advances
Verified
Journal Article
Open access
LALetícia de Almeida
Letícia de Almeida
ASAlexandre L. N. da Silva
Alexandre L. N. da Silva
TRTamara S. Rodrigues
Tamara S. Rodrigues
SOSamuel Oliveira
Samuel Oliveira
AIAdriene Y. Ishimoto
Adriene Y. Ishimoto
DZDario S. Zamboni
Dario S. Zamboni
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces mild or asymptomatic COVID-19 in most cases, but some patients develop an excessive inflammatory process that can be fatal. As the NLRP3 inflammasome and additional inflammasomes are implicated in disease aggravation, drug repositioning to target inflammasomes emerges as a strategy to treat COVID-19. Here, we performed a high-throughput screening using a 2560 small-molecule compound library and identified FDA-approved drugs that function as pan-inflammasome inhibitors. Our best hit, niclosamide (NIC), effectively inhibits both inflammasome activation and SARS-CoV-2 replication. Mechanistically, induction of autophagy by NIC partially accounts for inhibition of NLRP3 and AIM2 inflammasomes, but NIC-mediated inhibition of NAIP/NLRC4 inflammasome are autophagy independent. NIC potently inhibited inflammasome activation in human monocytes infected in vitro, in PBMCs from patients with COVID-19, and in vivo in a mouse model of SARS-CoV-2 infection. This study provides relevant information regarding the immunomodulatory functions of this promising drug for COVID-19 treatment.

1 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJefferson Antônio Leite
Jefferson Antônio Leite
NBNatalia Notarberardino Bos
Natalia Notarberardino Bos
LMLuísa Menezes-Silva
Luísa Menezes-Silva
ESEloísa Martins da Silva
Eloísa Martins da Silva
GLGiovana da Silva Leandro
Giovana da Silva Leandro
NCNiels Olsen Saraiva Camara
Niels Olsen Saraiva Camara
T helper 17 cells play essential roles in mucosal immunity and autoimmunity, yet the mechanisms that protect these cells from oxidative DNA damage remain poorly defined. Here we show, in a murine model, that the nucleotide excision repair sensor Xeroderma Pigmentosum Complementation Group C preserves genomic stability and metabolic fitness during T helper 17 cell differentiation. Loss of this factor reduces interleukin 17 production and increases mitochondrial reactive oxygen species and oxidative DNA damage, resulting in altered metabolic programs. Mechanistically, Xeroderma Pigmentosum Complementation Group C interacts with the base excision repair enzyme 8-oxoguanine DNA glycosylase, and its absence enhances oxidative lesion incision activity, indicating defective coordination between DNA repair pathways. Restoring antioxidant capacity rescues cytokine production and limits DNA damage in deficient cells. Together, these findings identify Xeroderma Pigmentosum Complementation Group C as a key coordinator of DNA repair and redox control required for T helper 17 cell function in inflammatory settings.